Skip to main
HCAT

HCAT Stock Forecast & Price Target

HCAT Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 11%
Hold 78%
Sell 0%
Strong Sell 0%

Bulls say

Health Catalyst is in the early stages of a business transformation that is expected to deliver profitable growth in the future. The recent earnings report showed a beat on revenue and EBITDA, but guidance for FY26 was slightly below consensus estimates and there is anticipated churn in DOS-related ARR. However, Health Catalyst has a strong track record of customer retention and valuable assets, making it a promising investment opportunity with a target price of $2, based on a 6.5x multiple of projected 2026 adjusted EBITDA of $33.5 million.

Bears say

Health Catalyst is facing significant challenges in terms of retaining and acquiring customers, as evidenced by a downward revision of their revenue estimates for both FY26 and FY27. This is due to a combination of factors including pressure on healthcare providers' budgets, lower margins on new professional services contracts, and competition from home-grown solutions and larger technology companies. While their strategic and operational review may potentially lead to divestitures or a sale of the company, the current uncertainty surrounding leadership and financial performance make it difficult to recommend investing in this stock.

HCAT has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 11% recommend Buy, 78% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Health Catalyst Inc (HCAT) Forecast

Analysts have given HCAT a Hold based on their latest research and market trends.

According to 9 analysts, HCAT has a Hold consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Health Catalyst Inc (HCAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.